Literature DB >> 9816116

Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Y Takahashi1, K R Cleary, M Mai, Y Kitadai, C D Bucana, L M Ellis.   

Abstract

Angiogenesis is essential for tumor growth and metastasis and depends on the production of angiogenic factors by host and/or tumor cells. The role of angiogenesis and angiogenic factor expression in intestinal- and diffuse-type gastric cancer are undefined. Archival specimens of 51 intestinal-type and 38 diffuse-type human gastric carcinomas were examined for tumor vessel counts, angiogenic factor expression, and the presence or absence of angiogenic factor receptors on tumor endothelium using antibodies against vascular endothelial growth factor (VEGF) and its receptors (KDR and flt-1), basic fibroblast growth factor (bFGF) and its receptors (bek and flg), and factor VIII (endothelial cells). Vessel count and VEGF and bFGF expression were higher in intestinal-type than in diffuse-type gastric cancers (P = 0.01, P < 0.001, and P < 0.001, respectively). Similarly, vessel count and VEGF expression were higher in patients with liver metastasis than in patients with peritoneal dissemination (P = 0.003 and P = 0.01, respectively). Vessel count correlated with VEGF expression and the presence of endothelial KDR in intestinal-type gastric cancer (P = 0.003 and P = 0.02, respectively) but not diffuse-type gastric cancer. Vessel count, VEGF expression, and presence of endothelial KDR increased with increasing stage of disease in intestinal-type gastric cancer but not diffuse-type gastric cancer. The expression of bFGF and its receptors did not correlate with vessel count in either cancer type. These findings suggest that the pattern of metastasis in intestinal-type gastric cancer is angiogenesis dependent. The correlation of VEGF expression and its endothelial receptor with vessel count and stage of disease suggests that VEGF is at least one of the factors responsible for the induction of angiogenesis in intestinal-type gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816116

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  87 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.

Authors:  Xiaolin Wan; Na Shen; Arnulfo Mendoza; Chand Khanna; Lee J Helman
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Authors:  Simon Pernot; Magali Terme; Nina Radosevic-Robin; Florence Castan; Cécile Badoual; Elie Marcheteau; Fréderique Penault-Llorca; Olivier Bouche; Jaafar Bennouna; Eric Francois; Francois Ghiringhelli; Christelle De La Fouchardiere; Emmanuelle Samalin; Jean Baptiste Bachet; Christophe Borg; Valérie Boige; Thibault Voron; Trevor Stanbury; Eric Tartour; Sophie Gourgou; David Malka; Julien Taieb
Journal:  Gastric Cancer       Date:  2019-07-02       Impact factor: 7.370

Review 5.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

Review 6.  Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

8.  Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer.

Authors:  Zheng-Jun Song; Ping Gong; Yu-E Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study.

Authors:  M A Konerding; E Fait; C Dimitropoulou; W Malkusch; C Ferri; R Giavazzi; D Coltrini; M Presta
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.

Authors:  Carolina Salvador; Bing Li; Richard Hansen; Daniel E Cramer; Maiying Kong; Jun Yan
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.